Unity Biotechnology Statistics
Share Statistics
Unity Biotechnology has 16.85M shares outstanding. The number of shares has increased by 0.39% in one year.
| Shares Outstanding | 16.85M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.02% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 15.37M |
| Failed to Deliver (FTD) Shares | 74 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 246.13K, so 1.46% of the outstanding shares have been sold short.
| Short Interest | 246.13K |
| Short % of Shares Out | 1.46% |
| Short % of Float | 1.6% |
| Short Ratio (days to cover) | 3.3 |
Valuation Ratios
The PE ratio is -0.72 and the forward PE ratio is -0.77.
| PE Ratio | -0.72 |
| Forward PE | -0.77 |
| PS Ratio | 0 |
| Forward PS | 3.5 |
| PB Ratio | 1 |
| P/FCF Ratio | -0.77 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Unity Biotechnology Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.94, with a Debt / Equity ratio of 0.95.
| Current Ratio | 5.94 |
| Quick Ratio | 5.94 |
| Debt / Equity | 0.95 |
| Total Debt / Capitalization | 48.73 |
| Cash Flow / Debt | -1.43 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.4% and return on capital (ROIC) is -80.64%.
| Return on Equity (ROE) | -1.4% |
| Return on Assets (ROA) | -0.61% |
| Return on Capital (ROIC) | -80.64% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.10M |
| Employee Count | 19 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -2.84% in the last 52 weeks. The beta is 0.83, so Unity Biotechnology 's price volatility has been higher than the market average.
| Beta | 0.83 |
| 52-Week Price Change | -2.84% |
| 50-Day Moving Average | 1.22 |
| 200-Day Moving Average | 1.42 |
| Relative Strength Index (RSI) | 62.26 |
| Average Volume (20 Days) | 145.92K |
Income Statement
| Revenue | n/a |
| Gross Profit | -19.70M |
| Operating Income | -44.67M |
| Net Income | -39.86M |
| EBITDA | -37.28M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.7 |
Balance Sheet
The company has 19.80M in cash and 26.99M in debt, giving a net cash position of -7.19M.
| Cash & Cash Equivalents | 19.80M |
| Total Debt | 26.99M |
| Net Cash | -7.19M |
| Retained Earnings | -484.35M |
| Total Assets | 47.13M |
| Working Capital | 21.48M |
Cash Flow
In the last 12 months, operating cash flow was -38.65M and capital expenditures -11.00K, giving a free cash flow of -37.10M.
| Operating Cash Flow | -38.65M |
| Capital Expenditures | -11.00K |
| Free Cash Flow | -37.10M |
| FCF Per Share | -2.51 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
UBX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -157.89% |
| FCF Yield | -128.75% |
Analyst Forecast
The average price target for UBX is $7, which is 309.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 309.4% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Oct 20, 2022. It was a backward split with a ratio of 1:10.
| Last Split Date | Oct 20, 2022 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -15.33 |
| Piotroski F-Score | 1 |